This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in stage IB-IIIA non-small cell lung cancer survivors. In many cancers such as lung cancer, there is a protein receptor called EGFR (epidermal growth factor receptor) that is overexpressed within these cancers. Activation of EGFR has shown to lead to tumor growth and development. Previous studies have indicated that EGFR activation is present in the airways of cancer-free subjects as well. CIMAvax-EGF vaccine works by causing the body to make antibodies against EGF that is being produced that could be possibly driving the risk for developing cancer.
A Phase 0 Study of CIMAvax-EGF vaccine in Patients Who Are At High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail firstname.lastname@example.org.